Novonesis A/S reports FY results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Financial Performance: Novonesis A/S reported FY 2024 pro forma sales of EUR 3,945.5 million, with Food & Health Biosolutions at 45% and Planetary Health Biosolutions at 55%. The company experienced an organic sales growth of 8%, but net financials were negative EUR 80.4 million due to increased interest costs.
Outlook for 2025: The company anticipates continued strong performance in 2025, projecting organic sales growth of 5-8% and an adjusted EBITDA margin of 37-38%, while both business segments are expected to grow within the group level range.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
